Published in Tissue Antigens on October 01, 2003
Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol (2006) 2.08
Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A (2006) 1.78
A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet (2006) 1.55
Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci (2010) 1.29
Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci U S A (2005) 1.20
The immune gene repertoire of an important viral reservoir, the Australian black flying fox. BMC Genomics (2012) 1.13
HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics (2004) 1.09
Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology (2013) 0.92
Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol (2007) 0.89
HLA-G Molecules in Autoimmune Diseases and Infections. Front Immunol (2014) 0.87
A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients. BMC Med Genomics (2013) 0.86
Modo-UG, a marsupial nonclassical MHC class I locus. Immunogenetics (2006) 0.85
The multi-faceted nature of HLA class I dimer molecules. Immunology (2012) 0.85
Evolution of the opossum major histocompatibility complex: evidence for diverse alternative splice patterns and low polymorphism among class I genes. Immunology (2008) 0.84
Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. Curr Oncol (2012) 0.82
Molecular characterization of major histocompatibility complex class I genes from the giant panda (Ailuropoda melanoleuca). Immunogenetics (2008) 0.82
The production, purification and crystallization of a soluble form of the nonclassical MHC HLA-G: the essential role of cobalt. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.80
Soluble HLA-G (sHLA-G) a predictor of IVF outcome? J Assist Reprod Genet (2004) 0.80
Pregnancy initiation in the rhesus macaque: towards functional manipulation of the maternal-fetal interface. Reprod Biol Endocrinol (2004) 0.80
Lack of association between promoter polymorphisms of HLA-G gene and rheumatoid arthritis in Korean population. Rheumatol Int (2011) 0.78
Human Parthenogenetic Embryonic Stem Cell-Derived Neural Stem Cells Express HLA-G and Show Unique Resistance to NK Cell-Mediated Killing. Mol Med (2015) 0.78
Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus. J Clin Immunol (2010) 0.77
Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites. Haematologica (2012) 0.76
Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease. Biomed Res Int (2016) 0.75
Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions. World J Methodol (2014) 0.75
Soluble human leukocyte antigen G level in fluid from single dominant follicle and the association with oocyte competence. Yonsei Med J (2011) 0.75
Recognition of the Major Histocompatibility Complex (MHC) Class Ib Molecule H2-Q10 by the Natural Killer Cell Receptor Ly49C. J Biol Chem (2016) 0.75
The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res (1981) 15.12
EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. J Biol Chem (1995) 5.45
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Viridans streptococcal bacteraemia in patients with neutropenia. Lancet (1995) 2.46
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Actin-based movement of Listeria monocytogenes: actin assembly results from the local maintenance of uncapped filament barbed ends at the bacterium surface. J Cell Biol (1995) 2.27
Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A (1997) 2.14
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia (2003) 2.07
Disease associations with complotypes, supratypes and haplotypes. Immunol Rev (1983) 1.87
Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med (1994) 1.74
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia (2010) 1.59
HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity (1998) 1.58
Prophage lambda induction of Escherichia coli K12 envA uvrB: a highly sensitive test for potential carcinogens. Proc Natl Acad Sci U S A (1976) 1.54
Autosomal dominant spondyloarthropathy. N Engl J Med (1989) 1.54
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
T-cell recognition of a chimaeric class II/class I MHC molecule and the role of L3T4. Nature (1985) 1.53
HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol (2001) 1.50
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sci U S A (1995) 1.49
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol (1999) 1.46
Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients. Bone Marrow Transplant (1995) 1.45
The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A (1997) 1.44
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia (2011) 1.43
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol (1999) 1.41
[Invasive aspergillosis in intensive care]. Ann Fr Anesth Reanim (1995) 1.39
A micro tissue culture test for the titration and neutralization of rubella virus. Can J Microbiol (1969) 1.33
Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A (2001) 1.32
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Simian virus 40 late promoter region able to initiate simian virus 40 early gene transcription in the absence of the simian virus 40 origin sequence. J Virol (1984) 1.29
Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol (2001) 1.27
Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol (1999) 1.26
Complement allotyping in SLE: association with C4A null. Aust N Z J Med (1983) 1.24
An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci U S A (1994) 1.23
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
HLA and complement allotypes in Type 1 (insulin-dependent) diabetes. Diabetologia (1983) 1.20
Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol (1997) 1.20
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol (1999) 1.19
Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. J Thorac Cardiovasc Surg (1998) 1.18
Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol (2000) 1.18
Transfection and overexpression of the human 60-kDa Ro/SS-A autoantigen in HEp-2 cells. Clin Immunol Immunopathol (1994) 1.17
Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis (1997) 1.17
HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol (1999) 1.16
HLA-G: a shield against inflammatory aggression. Trends Immunol (2001) 1.15
Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens (2001) 1.15
Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis (2001) 1.12
HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol (2001) 1.12
Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res (2001) 1.10
Rosette-forming T cells in human peripheral blood at different ages. Cell Immunol (1974) 1.10
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension (1997) 1.10
Communicating with cancer patients in Saudi Arabia. Ann N Y Acad Sci (1997) 1.10
Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci U S A (1991) 1.09
Implication of HLA-G molecule in heart-graft acceptance. Lancet (2000) 1.09
Pitfalls in the diagnosis of leg pain. Can Med Assoc J (1979) 1.08
Significant impact of survivin on myeloma cell growth. Leukemia (2007) 1.08
The genetic structure of 3'untranslated region of the HLA-G gene: polymorphisms and haplotypes. Genes Immun (2009) 1.07
Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. J Immunol (1994) 1.06
Analysis of hybrid H-2D and L antigens with reciprocally mismatched aminoterminal domains: functional T cell recognition requires preservation of fine structural determinants. J Immunol (1986) 1.06
A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem (2000) 1.05
Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys (2001) 1.05
Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J Immunol (2000) 1.04
NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia (2008) 1.04
The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J Immunol (1996) 1.04
HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol (2001) 1.04
Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. Pathology (1996) 1.03
18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol (2010) 1.03
HLA-G gene polymorphism segregation within CEPH reference families. Hum Immunol (1997) 1.02
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma (2011) 1.02
Restricted polymorphism of the mannose-binding lectin gene of indigenous Australians. Hum Mol Genet (2000) 1.02
Growth factors and cutaneous wound repair. Prog Growth Factor Res (1992) 1.01